ArticleTherapeutic advances in medical oncology2025

Pembrolizumab versus pembrolizumab plus chemotherapy in patients with PDL1 ⩾50% advanced non-small-cell lung cancer, depending on tumor aggressiveness and clinical impact.

Marine Lejeune et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.